The 10-second takeaway
For the quarter ended March 31 (Q1), Pfizer met expectations on revenues and beat slightly on earnings per share.
Compared to the prior-year quarter, revenue shrank and GAAP earnings per share dropped.
Margins dropped across the board.
Pfizer recorded revenue of $15.41 billion. The 15 analysts polled by S&P Capital IQ hoped for a top line of $15.43 billion on the same basis. GAAP reported sales were 6.6% lower than the prior-year quarter's $16.50 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.58. The 18 earnings estimates compiled by S&P Capital IQ averaged $0.57 per share. GAAP EPS of $0.24 for Q1 were 14% lower than the prior-year quarter's $0.28 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 80.7%, 60 basis points worse than the prior-year quarter. Operating margin was 20.4%, 1,310 basis points worse than the prior-year quarter. Net margin was 11.6%, 190 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $15.52 billion. On the bottom line, the average EPS estimate is $0.56.
Next year's average estimate for revenue is $62.16 billion. The average EPS estimate is $2.26.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 5,500 members out of 6,092 rating the stock outperform, and 592 members rating it underperform. Among 1,446 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 1,351 give Pfizer a green thumbs-up, and 95 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Pfizer is outperform, with an average price target of $24.33.
The drug and healthcare investing landscape is littered with also-rans and a few major winners. Is Pfizer the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add Pfizer to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Motley Fool newsletter services have recommended buying shares of Pfizer. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.